Care of patients with sepsis has improved over the last decade. However, in the recent two years, there was no significant progress in the development of a new drug for critically ill patients. In January 2011, it was announced that the worldwide phase 3 randomized trial of a novel anti-Toll-like receptor-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the mortality of patients with severe sepsis. In October 2011, Xigris (drotrecogin alfa, a recombinant activated protein C) was withdrawn from the market following the failure of its worldwide trial that had attempted to demonstrate improved outcome. These announcements were disappointing. The recent failure of 2 promising drugs to further reduce mortality suggests that new approaches are needed. A study was published showing that sepsis can be associated to a state of immunosuppression and loss of immune function in human. However, the timing, incidence, and nature of the immunosuppression remain poorly characterized, especially in humans. This emphasizes the need for a better understanding of sepsis as well as new therapeutic strategies. Many clinical experiences of the extracorporeal membrane oxygenator (ECMO) treatment for adult acute respiratory distress syndrome (ARDS) patients, which is caused by the H1N1 influenza A virus, were reported. The use of ECMO in severe respiratory failure, particularly in the treatment of adult ARDS, is occurring more commonly. 
Introduction
Acute respiratory distress syndrome (ARDS) and severe sepsis are major problems to be improved management in critical care medicine. Extracorporeal membrane oxygenation (ECMO) is an intensive treatment that is currently used to support patients with severe respiratory failure who are unresponsive to conventional therapeutic interventions. However, ECMO treatments for adult ARDS patients were controversial until a recent date even though the use of ECMO is occurring more commonly. The disappointing failures of clinical trials to further reduce mortality of severe sepsis suggest that new approaches are needed. In this article, I choose some papers showing promising results for severe respiratory failure and sepsis treatments published recent two years.
Articles Selection
I choose some critical care papers with clinical significances published in major journals for recent two years. The ECMO-referred patients and the non-ECMO-referred patients were matched using data from a concurrent, longitudinal cohort study (Swine Flu Triage study) of critically ill patients with suspected or confirmed H1N1. Detailed demographic, physiological, and comorbidity data were used in 3 different matching techniques (individual matching, propensity score matching, and GenMatch matching).
MAIN OUTCME MEASURE: Survival to hospital discharge analyzed according to the intention-to-treat principle.
RESULTS: Of 80 ECMO-referred patients, 69 received ECMO (86.3%) and 22 died (27.5%) prior to discharge from the hospital. From a pool of 1756 patients, there were 59 matched pairs of ECMO-referred patients and non-ECMOreferred patients identified using individual matching, 75 matched pairs identified using propensity score matching, and 75 matched pairs identified using GenMatch matching.
The hospital mortality rate was 23.7% for ECMO-referred patients vs 52.5% for non-ECMO-referred patients (relative risk Comments: ECMO is an intensive treatment that is currently used to support patients with respiratory or cardiac failure who are unresponsive to conventional therapeutic interventions. However, ECMO treatments for adult ARDS patients were controversial until a recent date even though the use of ECMO is occurring more commonly 2, 3 . In 2009, a randomized controlled study (known as Central European Society for Anticancer Research [CESAR] study) indicated that more patients with severe ARDS survived significantly if they were treated in an ECMO center compared with patients who were managed conventionally 4 . CESAR study was the first randomized controlled trial (RCT) report to show positive result of ECMO for ARDS.
This study by Noah et al. 1 present evidence in support of ECMO as a treatment strategy early in the course of ARDS related to H1N1 infection. However, this study has some limitations. Some ARDS patients were required transfer to specialized ECMO centers. The design of this study makes it unclear whether the mortality benefit associated with ECMO was attributable to management of severe respiratory failure in a specialized center or to the use of ECMO. To consider ECMO as a potential treatment modality for severe ARDS from all causes, large RCTs are needed.
Steroid Treatment for Severe Viral Pneumonia Comments: Another study with very similar design of this study was reported in the same issue of the journal consicutively 6 . Both studies represent corticosteroids were harmful in critically ill patients with influenza A H1N1 infection. Many clinicians used corticosteroids to patients with acute lung injury (ALI)/ARDS to reduce lung inflammation and hope improving clinical outcomes. However, no randomized clinical trials have been performed to confirm the effects of steroids in ALI/ARDS by acute viral pneumonia. Given the acute nature of the H1N1 influenza pandemic, a prospective randomized trial was not possible. To overcome this problem, the authors used several analytic techniques to adjust for differences in the steroid-treated and non-treated groups to compare clinical outcomes. These two studies showed very similar results in spite of different ethnic groups. So, my view is that steroids should not be used in severe viral pneumonia, unless new study provides evidence that steroids are beneficial.
Lactate Monitor in Sepsis Comments: Early goal-directed quantitative resuscitation refers to the use of a specific protocol that targets predefined physiological or laboratory goals to be achieved within the first several hours. Results of a recent meta-analysis indicated a survival benefit associated with the use of this strategy applied to heterogeneous populations of patients with sepsis 8 . The optimal method for determining tissue oxygen delivery remains uncertain. Published practice surveys have shown that the expertise technique and specialized equipment required to measure ScvO 2 make a major barrier to the completion of this protocol 9 . In contrast, lactate clearance, derived from calculating the change in lactate concentration from 2 blood specimens drawn at different times, potentially represents a more accessible method to assess tissue oxygen delivery. The authors of this study observed that management to normalize lactate clearance in initial sepsis treatment has suspicious benefit. However, only a small fraction (10%) of enrolled patients received therapies (dobutamine or transfusions) that influenced by the resuscitation targets being compared. So interpretation of the results is somewhat complicated. Nevertheless, the data support the noninferiority of the lactate guidance strategy. Medical Treatment for ARDS Comments: Beta-2 agonists activate Beta-2 receptors on alveolar type-1 and type-2 cells, which increases intracellular cAMP, leading to increased sodium transport and acceleration of alveolar fluid reabsorption. Findings from the β-agonist lung injury trial (BALTI) showed that an infusion of salbutamol caused significant reductions in extravascular lung 13 . However, the results of the truncated BALTI-2 trial are very disappointed and sufficient to change practice. Beta-2 agonist treatment in patients with ARDS should be limited to the treatment of clinically important reversible airway obstruction and should not be part of routine care. Comments: The potential value of aerosolized beta 2-agonist therapy for treatment of acute lung injury has not been tested previously in a phase III, randomized clinical trial. The results of this randomized doubleblind clinical trial demonstrate that aerosolized b2-agonist therapy with albuterol did not improve clinical outcomes in patients with acute lung injury. However, the majority of animal studies of ALI demonstrating a benefit used beta2-agonists as a pre-injury treatment. Though treatment role of beta-agonists for ALI has not been proved, the potential role in the prophylactic setting is expected. Several studies are ongoing to investigate this possibility. was 26.6% in the n-3 group vs 16.3% in the control group (P = .054), and adjusted 60-day mortality was 25.1% and 17.6% in the n-3 and control groups, respectively (P = .11).
Use of the n-3 supplement resulted in more days with diarrhea (29% vs 21%; P = .001).
CONCLUSIONS: Twice-daily enteral supplementation of n-3 fatty acids, gamma-linolenic acid, and antioxidants did not Comments: Because artificial nutrition showed potential effects on clinical outcomes in critically ill patients during the last decade, nutrition is now considered therapy not supportive care 16, 17 . Therefore, it was unexpected and disappointing that enrollment was suspended early in the OMEGA trial because of perceived futility. There are several possible explanations for these negative results. For example, although all patients in the OMEGA trial received a similar number of calories (but by design a different composition of lipids), the control group received up to 20 g of additional protein per day from the control solution. Delivery of a different amount of protein perhaps favorably influenced outcomes in that group. An alternative explanation is that because continuous administration of these supplements appeared beneficial in prior trials, perhaps the bolus delivery method used in this trial blunted the inflammation modulation effect.
Immuno Suppression in Sepsis Comments: Abundant evidence exists in sepsis for the appearance of high plasma levels of proinflammatory cytokines and chemokines characterized by clinical signs of fever, tachycardia, and tachypnea and followed rapidly by development of shock, multiorgan failure, and death. Additional evidence indicates that sepsis can be associated with a state of immunosuppression, broadly defined as lymphopenia and loss of immune function, though the timing, incidence, and nature of the immunosuppression remain poorly characterized, especially in humans. Numerous investigative agents have been directed at down modulating this initial hyperimmune phase. After numerous unsuccessful trials of anti-inflammatory agents in patients with sepsis, a major shift has occurred in the way investigators view the problem of sepsis 19 . Those who survive early sepsis often develop nosocomial infections with organisms not typically pathogenic in immunocompetent hosts and have reactivation of latent viruses. Sepsis may not be attributable solely to a "cytokine storm" but may indicate an immune system that is severely compromised and unable to eradicate pathogens. Although animal studies demonstrate progression to an immunosuppressive phase, epidemiologic studies in clinical sepsis are lacking 20 . In this study, the authors have presented an informative report documenting immunosuppression in humans with septic shock. A next step might be to determine why during sepsis immune cells switch to anti-immune cells. Another question is whether such derangements in sepsis can be reversed by treatment with immune restoring agents.
Inotropics for Shock Treatment Comments: Irrespective of the underlying cause, the treatment of shock includes initial resuscitation with vasopressor and volume. A critical question is which vasopressor should be used initially. Dopamine and norepinephrine may have different effects on the kidney, the splanchnic region, and the pituitary axis, but the clinical implications of these differences are still uncertain. Guidelines recommend that either agent may be used as a first-choice vasopressor in patients with shock. However, observational studies have shown that the administration of dopamine may be associated with higher rates of death than those associated with the administration of norepinephrine. In this study, the authors conclude that their study raises serious concerns about the safety of dopamine. However, a few important limitations of this study are noted. First, the authors defined the adequate administration of fluids as at least 1 L of crystalloids or 500 mL of colloids. This seems to be not sufficient for septic or hypovolemic shock. Second, the authors suggest that they used "equipotent" doses of vasopressors, equating 20μg per kilogram of body weight per minute of dopamine with 0.19μg per kilogram per minute of norepinephrine. However, the evidence of this equipotent does not exist. A remaining question is the role of vasopressin as a therapeutic agent for shock. In this study, the authors used vasopressin as rescue therapy, and only two patients in each group received vasopressin. Vasopressin is another direct-acting agent. Previous studies have compared that norepinephrine and vasopressin among patients with septic shock 22 . Vasopressin may be as effective as norepinephrine.
Summary
In recent two years, new positive data about ECMO for ARDS treatment were introduced. Moreover, a study showing that sepsis can be associated with another pathogenetic mechanism, a state of immuno-suppression and loss of immune function in human was published. These are expected that presentation of the direction for further study and development of treatment guidelines for critical care medicine.
